Sohomoy

New Research Exposes a Lipid-Based Drug Delivery Blind Spot

3 min read
0
Comments
57
Views

A 2026 study highlights a drug-delivery challenge: similar lipid particle measurements do not guarantee similar intestinal performance. Emulsion and dry-emulsion developers must also address precipitation, stability, and reproducibility.

 

Drug developers use lipid-based drug delivery (LDD) to tackle poorly water-soluble compounds, yet a formulation that performs well in initial screening may behave differently after dilution, digestion, or storage. New research highlights why choosing the right lipids is only part of the challenge.

 

A 2026 study by Khan and colleagues in Pharmaceutics compared curcumin-loaded nanoemulsions, nanostructured lipid carriers, and solid lipid nanoparticles in an ex vivo porcine intestinal model. Despite similar particle sizes and surface-charge measurements, the formulations showed different time-dependent permeation patterns. These findings do not establish human bioavailability, but they illustrate why conventional particle characterization alone cannot predict biological performance.

 

Solubility Does Not Eliminate Precipitation Risk

A poorly soluble active pharmaceutical ingredient (API) may dissolve in a lipid vehicle but precipitate when the formulation encounters gastrointestinal fluids. Changing pH, dilution, and lipid digestion can shift the balance between dissolved and precipitated drug, with consequences for the amount available for absorption.

 

A 2025 study by Taheri and colleagues in Pharmaceutics investigated this challenge using a silica-solidified lipid formulation of abiraterone acetate. In a rat pharmacokinetic experiment, the enteric-coated formulation produced greater systemic exposure than its non-coated comparator. Although the findings are preclinical and formulation-specific, they reinforce the importance of testing what happens after administration, not simply at the mixing bench.

 

Emulsion Stability Requires More Than Small Droplets

Emulsion formulations disperse one immiscible liquid within another, typically oil and water. Oil-in-water and water-in-oil systems can be considered for different payloads and routes, but successful preparation does not ensure long-term stability.

 

Droplet-size distribution, interfacial composition, viscosity, and processing conditions can affect creaming, flocculation, coalescence, and phase separation. Screening should therefore evaluate drug loading and physical stability under relevant storage and dilution conditions. Formulators also need to distinguish measurements made immediately after production from those obtained after the emulsion has aged.

 

Dry Emulsions Introduce New Development Questions

Dry emulsions are powder formulations designed to reconstitute into oil-in-water emulsions after hydration. Spray drying or lyophilization may help address some handling and storage limitations associated with aqueous systems, but removing water does not automatically solve stability problems.

 

A drying process may affect drug integrity, powder flow, and droplet properties after redispersion. Developers should check whether the intended emulsion reforms consistently and whether storage changes drug content or reconstitution behavior.

 

Build Translation into the Screening Plan

For oral candidates, meaningful early tests may include dilution-induced precipitation, in vitro lipolysis where relevant, drug loading, and release behavior. Emulsion and dry-emulsion projects also benefit from tracking droplet-size distributions, redispersion, and batch-to-batch consistency. These measurements help expose potential scale-up issues before teams commit to a manufacturing route.

 

Creative Biolabs offers customized lipid-based drug delivery formulation services for research, including emulsion and dry-emulsion options. Explore Creative Biolabs' lipid-based drug delivery formulation services and discuss project-specific challenges to identify an appropriate development strategy.